PTX


Pernix Therapeutics Holdings Inc Reaches Settlement in Zohydro Patent Litigation

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that it has entered into a settlement agreement with Actavis Laboratories FL (“Actavis”) resolving patent litigation related …

Pernix Therapeutics Holdings Inc (PTX) Announces a Cost-Saving Initiative

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that, due to the impending loss of exclusivity of TREXIMET® (sumatriptan and naproxen sodium), the Company is …

Pernix Therapeutics Holdings Inc (PTX) Announces 2Q:17 Financial Results and Provides Business Update

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced financial results for the three and six months ended June 30, 2017. Second Quarter 2017 Financial Highlights: Second …

Pernix Therapeutics Holdings Inc Joins Russell Microcap Index

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced today that it has been added to the Russell Microcap® index following the annual reconstitution, which took …

Pernix Therapeutics Holdings Inc (PTX) Shares Take a Hit on Default Warning

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) shares are tumbling 25% in after-hours trading after the drug maker said that a failure to raise capital and repay all …

Pernix Therapeutics Holdings Inc’s (PTX) 20mg Zohydro ER with BeadTek Delayed by Manufacturing Snag

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that, due to a manufacturing issue with its supplier, the Company expects that the 20mg strength of …

Pernix Therapeutics (PTX) Reports 4Q and Full Year 2016 Results

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) announced financial results for the three and twelve months ended December 31, 2016.

Pernix Therapeutics Holdings Inc (PTX) Shares Jump on Back of Favorable Opinion in Zohydro ER Litigation

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) investors have a smile on their faces Thursday morning, after the pharmaceutical firm announced that it received a favorable …

Friday’s Market Insights: Cerulean Pharma Inc (CERU), Pernix Therapeutics Holdings Inc (PTX) and GoPro Inc (GPRO)

Cerulean Pharma Inc (NASDAQ:CERU) are catapulting 60% after the cancer drug-maker has decided to confront recent missteps with the consideration of M&A possibilities. …